Jesse Novak
About Jesse Novak
Jesse Novak is a Manager at Bristol Myers Squibb in Summit, New Jersey, with extensive experience in protein purification and bioconjugation.
Company
Jesse Novak currently works at Bristol Myers Squibb, a well-known biopharmaceutical company, in Summit, New Jersey, United States. Previously, Jesse held multiple roles at the same company, showcasing a deep-rooted connection and extensive experience within the organization.
Title and Current Role
Jesse Novak holds the position of Manager at Bristol Myers Squibb, located in Summit, New Jersey. This role signifies Jesse's growth within the company, having transitioned from previous scientific roles.
Previous Roles and Experience
Jesse Novak has worked in various scientific and managerial roles. Notably, Jesse was a Senior Associate Scientist at Bristol Myers Squibb from 2019 to 2021 and a Senior Associate in Downstream Processing from 2014 to 2018. Before rejoining Bristol Myers Squibb, Jesse worked as a Bioconjugation Scientist at Abzena in Bristol, PA, between 2018 and 2019. Earlier experience includes an Associate Research Scientist position at Princeton BioMeditech from 2012 to 2014.
Education and Expertise
Jesse Novak holds a Bachelor of Science degree in Molecular Biology from Montclair State University. With ten years of experience in protein purification, particularly monoclonal antibodies (mAbs), Jesse is a recognized subject matter expert (SME) with extensive expertise in GE AKTA systems and UNICORN software. This educational background and specialized knowledge support Jesse's current and previous professional roles.
Technical Skills and Experience
Jesse Novak brings a robust technical skill set, including expertise in Tangential Flow Filtration (TFF) systems and filtration techniques. Additionally, Jesse has experience in small-scale mammalian cell culture and development, protein analytics, and cGMP manufacturing of clinical material. This diverse range of skills is underpinned by a solid understanding of quality control processes, making Jesse a valuable asset in the biopharmaceutical industry.